Stroke Disorder and Treatment Market Size was valued at USD 22.11 billion in 2023 and is projected to grow from USD 23.85 Billion in 2024 to USD 40.63 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.88% during the forecast period (2024 - 2032). Increasing number of stroke patients, and growing investment by market players for the development of new therapy and advanced technology are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The demand for efficient stroke treatment options, such as medications, medical equipment, and rehabilitation therapies, is increasing as more people suffer from strokes. The need for stroke diagnostic and monitoring devices decreased. Device manufacturing facilities were forced to close during the global lockdown. This lockdown brought on the market participants' financial disaster. This further caused problems with the movement of devices across the nations. While medical device producers create cutting-edge tools for stroke prevention and treatment, pharmaceutical businesses invest in creating new stroke medicines. Additionally, rehabilitation facilities are increasing the spectrum of therapies they give to individuals recovering from strokes so they can regain their independence.
Blood tests, computed tomography scans, MRI, ultrasound, cerebral angiograms, and echocardiograms are used to diagnose strokes. The stroke therapy sector pharmaceutical companies should concentrate more on American medication development. Health commissions' favorable recommendations and the U.S.'s well-established healthcare system are attracting the attention of stroke therapy market participants worldwide. However, delayed tPA drug treatment in individuals with acute ischemic stroke might result in fatalities, hemorrhagic transition (HT), intracranial hemorrhage (ICH), and other health issues. Companies are teaching medical practitioners about the use of tPA medications within 4.5 hours of the onset of a stroke to get around this problem.
Using medically superior mesenchymal stem cells (MSCs) produced from the cranial bone, Hiroshima University (HU) began the human study for a promising therapy that can potentially restore paralysis and language disorder after mild to severe stroke. On September 7, HU released a statement regarding the clinical trial. In August, the trial's first patient received the first intravenous dosage of MSCs. The proposed therapy treats moderate to severe cerebral infarction, where neurological dysfunction recovery was highly unlikely with standard treatment, using patients' cultured MSCs extracted from their cranial bone, which is called autologous cranial bone-derived MSCs.
The rising number of stroke patients is a key factor driving the growth of the stroke treatment market. Stroke is a major health problem that affects millions of people worldwide, and it is a leading cause of disability and death. According to the World Stroke Organization, stroke is the second leading cause of death and the third leading cause of disability globally. As the global population continues to age, the prevalence of stroke is expected to increase. The World Health Organization estimates that the number of stroke cases worldwide will increase by 25% over the next 20 years, with the greatest increases expected in low- and middle-income countries. In addition to aging, other risk factors for stroke include hypertension, diabetes, smoking, and high cholesterol, among others. As these risk factors continue to be prevalent, the number of stroke cases is likely to increase further. According to Centers for Disease Control and Prevention (CDC), In 2019, stroke was the fifth leading cause of death in the United States, with over 147,000 deaths attributed to stroke. Also, in 2018, over 795,000 people in the US had a stroke, with 610,000 of these being first-time strokes.
The rising number of stroke patients is driving demand for effective stroke treatment options, including medications, medical devices, and rehabilitation therapies. Pharmaceutical companies are investing in the development of new stroke treatments, while medical device manufacturers are developing innovative devices for use in stroke treatment and prevention. In addition, rehabilitation centers are expanding their services to meet the needs of stroke patients, offering a range of therapies to help patients recover and regain their independence.
However, another major driver of the market during the forecast period are the increase in the elderly population, chronic diseases, neurological disorders, etc. The market is also growing as a result of numerous symptoms like tiredness, dilated pupils, impaired vision, losing balance when walking, paralysis, and stiff neck. Moreover, an unhealthy diet, an increase in alcohol use, a rise in smoking, and an increase in the number of diabetics are all factors that will affect market growth in the near future. Peripheral neuropathy is thought to account for 46.2% of the total 3000 people, chronic headaches for 26.4%, epilepsy for 8.5%, stroke for 6.6%, and tremors/disease Parkinson's for 3.8%, according to BMC Neurology study. Also, the market will rise during the forecast period due to technical developments along with manufacturer research and development efforts to provide new advanced technological devices and medications for people suffering from strokes. Similar to this, the government's growing efforts to raise public awareness through organizations like the American Heart Association, CDC, and WHO are also focusing on market expansion.
The Stroke Disorder and Treatment Market segmentation, based on type, includes ischemic stroke, hemorrhagic strokes. The ischemic stroke segment held the majority share in 2022 contribution to significant share in respect to the Stroke Disorder and Treatment Market revenue. This is primarily owing to the increased demand for acute stroke treatments, development of new stroke therapies, and advancements in stroke rehabilitation is anticipated to support the market growth during forecast period.
January 2019: The US Food and Drug Administration (FDA) approved a new thrombectomy device called the Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology, for the treatment of acute ischemic stroke.
April 2019:Â Researchers at the University of Texas Health Science Center at Houston announced the development of a new drug, called 6S-hydroxy-l-nicotine, that may improve outcomes for ischemic stroke patients by reducing inflammation in the brain.
The Stroke Disorder and Treatment Market segmentation, based on Medicine, includes anticoagulants, anti-hypertensive. The anticoagulants segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to the Increasing use of endovascular thrombectomy, development of novel anticoagulant therapies, and expanding use of anticoagulants in stroke prevention that anticipated to support the market growth during forecast period.
In May 2019, the US FDA approved Andexxa, an antidote for the reversal of the anticoagulant effects of rivaroxaban and apixaban in patients with life-threatening or uncontrolled bleeding. Andexxa is manufactured by Portola Pharmaceuticals.
In June 2020, AMAG Pharmaceuticals announced that it had received FDA approval for Vyleesi, a self-administered injectable treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. While Vyleesi is not an anticoagulant, it is relevant to the Stroke Treatment Market as it is contraindicated in patients at increased risk of cardiovascular disease or stroke.
The Stroke Disorder and Treatment Market data has been bifurcated by treatment into tissue plasminogen activator (TPA), endovascular procedures. The tissue plasminogen activator (TPA) segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Tissue plasminogen activator (TPA) is a clot-busting drug that is used to treat ischemic strokes. Ischemic strokes occur when a blood clot blocks a blood vessel in the brain, leading to a lack of blood flow and oxygen to the affected area of the brain. TPA is a medication that helps to dissolve the clot and restore blood flow to the affected area, potentially limiting the damage caused by the stroke.
In 2019, a study was published in the New England Journal of Medicine showing that the use of a higher dose of TPA in patients with ischemic strokes did not result in better outcomes compared to the standard dose. This study has important implications for the use of TPA in the treatment of strokes and may impact treatment guidelines in the future.
In 2020, the American Heart Association released updated guidelines for the early management of acute ischemic stroke, which includes recommendations for the use of TPA in eligible patients.
Figure 1: Stroke Disorder and Treatment Market, by Treatment, 2022 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
News
The third largest cause of mortality in the United States and the primary cause of disability, stroke, may soon be treated with a novel variation of a medicine used to treat alcohol use disorder. This new formulation, known as "Carb" for short, is intended to alleviate ischemic stroke, safeguard brain tissue from damage, and reduce the extent of a brain infarct. Ischemic stroke, when an artery carrying blood to the brain is blocked, accounts for roughly eighty-seven percent of all strokes.
Stroke Disorder and Treatment Regional Insights
By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Stroke Disorder and Treatment market accounted for USD 9.39 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. This is attributed to an increase in the prevalence of chronic diseases like diabetes, a surge in the demand for stroke management devices, the availability of government healthcare facilities with skilled medical personnel, an increase in the number of R&D activities along with the significant participation of key players, and an increase in government investment in the healthcare system.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: STROKE DISORDER AND TREATMENT MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe stroke disorder and treatment market accounts for the second-largest market share due to enhanced healthcare infrastructure, greater per capita income, and increased health awareness. Further, the Germany stroke disorder and treatment market held the largest market share, and the UK stroke disorder and treatment market was the fastest growing market in the European region
The Asia-Pacific Stroke Disorder and Treatment Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to improvements in the healthcare infrastructure, an increase in the number of hospitals using cutting-edge technology, the growth of the R&D industry, a rise in healthcare reforms, and developments in the field of stroke management technology. Moreover, China stroke disorder and treatment market held the largest market share, and the India stroke disorder and treatment market was the fastest growing market in the Asia-Pacific region
Stroke Disorder and Treatment Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the stroke disorder and treatment market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the stroke disorder and treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the global stroke disorder and treatment industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, stroke disorder and treatment industry has provided medicine and treatment with some of the most significant benefits. The stroke disorder and treatment market major player such as Novartis AG, Astra Zeneca, Bayer Pharma AG and others are working to expand the market demand by investing in research and development activities.
Novartis AG is a Swiss multinational pharmaceutical company that develops and produces a wide range of pharmaceuticals, including prescription drugs, over-the-counter medications, and generics. The company was founded in 1996 through the merger of Ciba-Geigy and Sandoz and is headquartered in Basel, Switzerland. Novartis AG's product portfolio includes drugs for various therapeutic areas, including cardiology, oncology, neurology, dermatology, ophthalmology, respiratory, and immunology. Some of the company's most well-known products include Diovan, Gilenya, Lucentis, and Cosentyx. In March 2019, Novartis announced positive results from its Phase III clinical trial of canakinumab, a drug that reduces inflammation in the body. The trial showed that canakinumab can reduce the risk of cardiovascular events, including stroke, in patients with a history of heart attack.
Also, Bayer Pharma AG is a German multinational pharmaceutical company that produces and develops a wide range of products, including prescription and over-the-counter medications, medical devices, and agricultural chemicals. The company was founded in 1863 and is headquartered in Leverkusen, Germany. Bayer Pharma AG's product portfolio includes drugs for various therapeutic areas, including cardiology, oncology, hematology, ophthalmology, pulmonology, and women's health. Some of the company's most well-known products include Aspirin, Xarelto, Eylea, and Yasmin. In August 2019, Bayer announced positive results from its Phase III clinical trial of the drug vericiguat, which is used to treat patients with heart failure. The trial showed that vericiguat can reduce the risk of cardiovascular death and hospitalization for heart failure, including stroke.
Key Companies in the stroke disorder and treatment market includes
Stroke Disorder and Treatment Industry Developments
In April 2019, Medtronic launched its Solitaire X revascularization device, which is used to remove blood clots in stroke patients. The device is designed to provide physicians with more control and precision during the procedure.
In May 2019, Stryker launched its Neuroform Atlas stent system. The stent system is used to treat brain aneurysms and is designed to conform to the unique anatomy of each patient's brain.
North America
Europe
Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Attribute/Metric | Details |
| Market Size 2023 | USD 22.11 billion |
| Market Size 2024 | USD 23.85 billion |
| Market Size 2032 | USD 40.63 billion |
| Compound Annual Growth Rate (CAGR) | 6.88% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Medicine, Treatment, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Novartis AG, Astra Zeneca, Daiichi Sankyo, Pfizer, Bayer Pharma AG |
| Key Market Opportunities | Growing research and development |
| Key Market Dynamics | Increasing number of stroke patients Growing investment by market players for the development of new therapy and advanced technology |
Frequently Asked Questions (FAQ) :
The Stroke Disorder and Treatment Market size was valued at USD 22.11 Billion in 2023.
The global market is projected to grow at a CAGR of 6.88% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are Novartis AG, Astra Zeneca, Daiichi Sankyo, Pfizer, Bayer Pharma AG.
The ischemic stroke category dominated the market in 2023.
The an-ticoagulants had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
